| Name | Title | Contact Details |
|---|---|---|
Lois Gianneschi |
Vice President, Patent Counsel | Profile |
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
MD Buyline is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arcturus Manufacturing is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Daniels Sharpsmart Inc is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Simavita is a medical device company operating in the digital healthcare sector that has developed an innovative world first solution for the management of urinary incontinence, with a focus on the elderly. Our flagship product is the SIM™ platform technology, an instrumented Incontinence assessment application that provides evidence based Incontinence management care plans to the residential aged care market. Simavita is committed to continuously innovating and expanding its core SIM™ platform technology to improve the level of Incontinence care, create efficiencies, promote effective utilisation of our society`s finite resources and enhance the dignity of care for our ageing population.